Multiple myeloma is the second most common blood cancer, accounting for 10% of all hematologic malignancies. It is caused by the abnormal expansion of plasma cells, which are specialized white blood cells that normally produce antibodies to help fight infections. Despite treatment advances that improved quality of life and overall survival, multiple myeloma remains challenging to manage over time due to relapse and refractory disease.
CAL056 is an oral, first-in-class HECT domain-containing E3 ubiquitin ligase inhibitor that has been granted Orphan Drug Designation by the US Food and Drug Administration for treatment of multiple myeloma. With a distinct mechanism of action from existing drugs, CAL056 offers an alternative treatment option as a single agent or in combination with current drugs for the treatment of a relapsed/refractory multiple myeloma.
